Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.

Current standards and regulations demand the pharmaceutical industry not only to produce highly pure drug substances, but to achieve a thorough understanding of the impurities accompanying their manufactured drug substances and products. These challenges have become important goals of process chemistry and have steadily stimulated the search of impurities after accelerated or forced degradation procedures. As a result, impurity profiling is one of the most attractive, active and relevant fields of modern pharmaceutical analysis. This activity includes the identification, structural elucidation and quantitative determination of impurities and degradation products in bulk drugs and their pharmaceutical formulations. Nuclear magnetic resonance (NMR) spectroscopy has evolved into an irreplaceable approach for pharmaceutical quality assessment, currently playing a critical role in unequivocal structure identification as well as structural confirmation (qualitative detection), enabling the understanding of the underlying mechanisms of the formation of process and/or degradation impurities. NMR is able to provide qualitative information without the need of standards of the unknown compounds and multiple components can be quantified in a complex sample without previous separation. When coupled to separative techniques, the resulting hyphenated methodologies enhance the analytical power of this spectroscopy to previously unknown levels. As a result, and by enabling the implementation of rational decisions regarding the identity and level of impurities, NMR contributes to the goal of making better and safer medicines. Herein are discussed the applications of NMR spectroscopy and its hyphenated derivate techniques to the study of a wide range pharmaceutical impurities. Details on the advantages and disadvantages of the methodology and well as specific challenges with regards to the different analytical problems are also presented.

[1]  U. Holzgrabe,et al.  NMR spectroscopy in pharmaceutical analysis , 2008 .

[2]  Srinivasulu Doddaga,et al.  Chloroquine-N-oxide, a major oxidative degradation product of chloroquine: identification, synthesis and characterization. , 2013, Journal of pharmaceutical and biomedical analysis.

[3]  Neha Parashar,et al.  Forced degradation studies to assess the stability of drugs and products , 2013 .

[4]  N. Gonnella LC-NMR: Expanding the Limits of Structure Elucidation , 2013 .

[5]  J. M. Babu,et al.  Characterization and relative response factor determination of process related impurity in Naproxen by nuclear magnetic resonance spectroscopy. , 2011, Journal of pharmaceutical and biomedical analysis.

[6]  P. Umesh,et al.  Isolation and structural elucidation of two impurities from a diacerein bulk drug. , 2009, Journal of pharmaceutical and biomedical analysis.

[7]  Ashok Kumar,et al.  Structural elucidation of process-related impurities in escitalopram by LC/ESI-MS and NMR. , 2010, Journal of pharmaceutical and biomedical analysis.

[8]  S. Jacobsson,et al.  Quantification of aldehyde impurities in poloxamer by 1H NMR spectrometry , 2005 .

[9]  B. Gander,et al.  A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation , 1996 .

[10]  Andrew Teasdale,et al.  Genotoxic Impurities: Strategies for Identification and Control , 2011 .

[11]  Andreas M. Abend,et al.  Identification of impurities in ivermectin bulk material by mass spectrometry and NMR. , 2006, Journal of pharmaceutical and biomedical analysis.

[12]  I. Wilson,et al.  On-flow identification of metabolites of paracetamol from human urine using directly coupled CZE–NMR and CEC–NMR spectroscopy , 1998 .

[13]  Acharya Subasranjan,et al.  An improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers. , 2010, Drug testing and analysis.

[14]  M. Johansson,et al.  Screening of counterfeit corticosteroid in creams and ointments by NMR spectroscopy. , 2012, Journal of pharmaceutical and biomedical analysis.

[15]  P. K. Owens,et al.  Strategies for the investigation and control of process-related impurities in drug substances. , 2007, Advanced drug delivery reviews.

[16]  P. Wei,et al.  Identification, Isolation, and Characterization of Impurities in Sodium Tanshinone IIA Sulfonate , 2009 .

[17]  L. Tseng,et al.  Gradient elution capillary electrochromatography and hyphenation with nuclear magnetic resonance , 1999, Electrophoresis.

[18]  G. Vamsi Krishna,et al.  Isolation and characterisation of degradant impurities in dipyridamole formulation. , 2012, Journal of pharmaceutical and biomedical analysis.

[19]  Jing Luo,et al.  HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug. , 2009, Journal of pharmaceutical and biomedical analysis.

[20]  Ming Xia,et al.  The stability of biapenem and structural identification of impurities in aqueous solution. , 2009, Journal of pharmaceutical and biomedical analysis.

[21]  Mario Cindrić,et al.  Identification of impurities in acarbose by using an integrated liquid chromatography-nuclear magnetic resonance and liquid chromatography-mass spectrometry approach. , 2005, Journal of separation science.

[22]  J. Haginaka,et al.  Enantiomeric purity determination of acetyl-L-carnitine by NMR with chiral lanthanide shift reagents. , 2005, Journal of pharmaceutical and biomedical analysis.

[23]  M. Gupta,et al.  Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS. , 2007, Journal of pharmaceutical and biomedical analysis.

[24]  Ravi P. Shah,et al.  Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR. , 2010, Journal of pharmaceutical and biomedical analysis.

[25]  Lianming Wu,et al.  Structural analysis of photo-degradation in thiazole-containing compounds by LC-MS/MS and NMR. , 2007, Journal of pharmaceutical and biomedical analysis.

[26]  N. Nardi,et al.  Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. , 2008, International journal of pharmaceutics.

[27]  S. LaPlante,et al.  Quantifying trifluoroacetic acid as a counterion in drug discovery by 19F NMR and capillary electrophoresis. , 2007, Journal of pharmaceutical and biomedical analysis.

[28]  Z. Yao,et al.  Unified Mechanistic Framework for the Fe(II)-Induced Cleavage of Qinghaosu and Derivatives/Analogues. The First Spin-Trapping Evidence for the Previously Postulated Secondary C-4 Radical , 1998 .

[29]  J. Sweedler,et al.  Hyphenation of capillary separations with nuclear magnetic resonance spectroscopy. , 2003, Journal of chromatography. A.

[30]  D. Mital,et al.  Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data , 2011, Analytical and bioanalytical chemistry.

[31]  W. Ye,et al.  Isolation and structure characterization of related impurities in Sodium Tanshinone IIA Sulfonate by LC/ESI-MS(n) and NMR. , 2012, Journal of Pharmaceutical and Biomedical Analysis.

[32]  R. Nogueira,et al.  Development of a new sodium diclofenac certified reference material using the mass balance approach and ¹H qNMR to determine the certified property value. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Ashok Kumar,et al.  Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS. , 2009, Journal of pharmaceutical and biomedical analysis.

[34]  H. Nasri,et al.  Isolation and Characterization of Cetirizine Degradation Product: Mechanism of Cetirizine Oxidation , 2010, Pharmaceutical Research.

[35]  S. Hansen,et al.  Identification of reaction products between drug substances and excipients by HPLC-SPE-NMR: ester and amide formation between citric acid and 5-aminosalicylic acid. , 2009, Journal of pharmaceutical and biomedical analysis.

[36]  T. Kaufman,et al.  Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium. , 2008, Journal of pharmaceutical and biomedical analysis.

[37]  D. Gorog Recent Advances in the Impurity Profiling of Drugs , 2008 .

[38]  H. Konno,et al.  Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. , 2008, Journal of pharmaceutical and biomedical analysis.

[39]  D. Greenwood,et al.  Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR , 2012, Analytical and Bioanalytical Chemistry.

[40]  Z. Béni,et al.  New oxidative decomposition mechanism of estradiol through the structural characterization of a minute impurity and its degradants. , 2013, Journal of pharmaceutical and biomedical analysis.

[41]  J. Hoogmartens,et al.  Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation , 2011, Analytical and Bioanalytical Chemistry.

[42]  V. L. Bagirova,et al.  Isolation and Identification of Impurities in the Parent Substance of Echinochrome and in the Drug Histochrome , 2004, Pharmaceutical Chemistry Journal.

[43]  D. Keire,et al.  Analyses of marketplace tacrolimus drug product quality: bioactivity, NMR and LC-MS. , 2013, Journal of pharmaceutical and biomedical analysis.

[44]  L. Tseng,et al.  Influence of pressure upon coupling pressurized capillary electrochromatography with nuclear magnetic resonance spectroscopy. , 2001, Analytical chemistry.

[45]  G. Torri,et al.  Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations , 2001, Seminars in thrombosis and hemostasis.

[46]  S. Kumar,et al.  LC determination of glimepiride and its related impurities. , 2005, Journal of pharmaceutical and biomedical analysis.

[47]  F. Malz,et al.  Validation of quantitative NMR. , 2005, Journal of pharmaceutical and biomedical analysis.

[48]  P. Jenks,et al.  Using high-performance ¹H NMR (HP-qNMR®) for the certification of organic reference materials under accreditation guidelines--describing the overall process with focus on homogeneity and stability assessment. , 2014, Journal of pharmaceutical and biomedical analysis.

[49]  D. Kanase,et al.  Isolation and characterization of benazepril unknown impurity by chromatographic and spectroscopic methods. , 2006, Journal of pharmaceutical and biomedical analysis.

[50]  Vishal D. Shah,et al.  Isolation and structure elucidation of major alkaline degradant of ezetimibe. , 2011, Journal of pharmaceutical and biomedical analysis.

[51]  N. M. Sekhar,et al.  Isolation and characterization of impurities in docetaxel. , 2006, Journal of pharmaceutical and biomedical analysis.

[52]  Del Grosso Erika,et al.  Forced degradation study of thiocolchicoside: characterization of its degradation products. , 2012, Journal of pharmaceutical and biomedical analysis.

[53]  U. Holzgrabe,et al.  Impurity profile of amino acids? , 2005, Pharmeuropa scientific notes.

[54]  Ashok Kumar,et al.  Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR. , 2009, Journal of pharmaceutical and biomedical analysis.

[55]  M. Ilijaš,et al.  LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. , 2009, Journal of pharmaceutical and biomedical analysis.

[56]  V. K. Handa,et al.  Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride. , 2008, Journal of pharmaceutical and biomedical analysis.

[57]  Kazunori Arifuku,et al.  Absolute quantitation of stevioside and rebaudioside A in commercial standards by quantitative NMR. , 2013, Chemical & pharmaceutical bulletin.

[58]  G. Balogh,et al.  The changing role of NMR spectroscopy in off-line impurity identification: A conceptual view , 2006 .

[59]  K. G. Prasad,et al.  Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, ¹H and ¹³C NMR spectroscopic characterization of degradation products and process related impurities. , 2013, Journal of pharmaceutical and biomedical analysis.

[60]  Xiaohong Zhu,et al.  Isolation, structural determination, synthesis and quantitative determination of impurities in Intron-A, leached from a silicone tubing. , 2009, Journal of pharmaceutical and biomedical analysis.

[61]  M. Haas,et al.  The isolation and identification of a toxic impurity in XP315 drug substance. , 2002, Journal of pharmaceutical and biomedical analysis.

[62]  S. Sabbah,et al.  RP-HPLC and NMR study of cis-trans isomerization of enalaprilat. , 2003, Journal of pharmaceutical and biomedical analysis.

[63]  A. Alexander,et al.  The design of an on‐line semi‐preparative LC–SPE–NMR system for trace analysis , 2005, Magnetic resonance in chemistry : MRC.

[64]  A. Naidu,et al.  Isolation, structural elucidation and characterization of impurities in Cefdinir. , 2007, Journal of pharmaceutical and biomedical analysis.

[65]  J. Lindon,et al.  Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements. , 1999, Journal of pharmaceutical and biomedical analysis.

[66]  U. Holzgrabe,et al.  Quantitative NMR spectroscopy of biologically active substances and excipients , 2010 .

[67]  Identification of a Unique Cationic Impurity in Preladenant™ Using Accurate MS and NMR , 2013 .

[68]  G. Kalabin,et al.  Quantitative nmr spectroscopy for quality control of drugs and pharmaceuticals , 2011, Pharmaceutical Chemistry Journal.

[69]  Koichi Saito,et al.  Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil. , 2006, Journal of chromatography. A.

[70]  J. Wang,et al.  Photodegradation of Fleroxacin Injection: Different Products with Different Concentration Levels , 2011, AAPS PharmSciTech.

[71]  D. Elder,et al.  Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. , 2011, Journal of pharmaceutical and biomedical analysis.

[72]  E. Antoniadou-Vyza,et al.  HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets. , 2008, Journal of pharmaceutical and biomedical analysis.

[73]  C. Szántay,et al.  Structure of the major degradant of ezetimibe. , 2012, Journal of pharmaceutical and biomedical analysis.

[74]  U. Holzgrabe,et al.  Determination of free fatty acids in edible oils by 1H NMR spectroscopy , 2012 .

[75]  I. A. Revel’skii,et al.  Determination of organic impurities in pharmaceutical preparations , 2005 .

[76]  Sarfaraz Niazi,et al.  Impurities in New Drug Substances , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[77]  Richard J. Smith,et al.  Analysis of drug impurities , 2007 .

[78]  R. Linhardt,et al.  Structural characterization of heparins from different commercial sources , 2011, Analytical and bioanalytical chemistry.

[79]  G. R. Bedford,et al.  Preparation and Identification of cis and trans Isomers of a Substituted Triarylethylene , 1966, Nature.

[80]  U. Holzgrabe Quantitative NMR spectroscopy in pharmaceutical applications. , 2010, Progress in nuclear magnetic resonance spectroscopy.

[81]  V. K. Handa,et al.  Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance. , 2008, Journal of pharmaceutical and biomedical analysis.

[82]  A. Naidu,et al.  Structural identification and characterization of impurities in ceftizoxime sodium. , 2007, Journal of pharmaceutical and biomedical analysis.

[83]  Neil E. Jacobsen,et al.  NMR spectroscopy explained : simplified theory, applications and examples for organic chemistry and structural biology , 2007 .

[84]  Kuiwu Wang,et al.  Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique. , 2005, Journal of pharmaceutical and biomedical analysis.

[85]  J. Berridge Impurities in drug substances and drug products: new approaches to quantification and qualification. , 1995, Journal of pharmaceutical and biomedical analysis.

[86]  P. Mourier,et al.  Heparin sodium compliance to USP monograph: structural elucidation of an atypical 2.18 ppm NMR signal. , 2012, Journal of pharmaceutical and biomedical analysis.

[87]  D. Coleman,et al.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis. , 2014, Journal of pharmaceutical and biomedical analysis.

[88]  M. Jarosinski,et al.  HPLC/NMR in Combinatorial Chemistry , 1998 .

[89]  R. Nageswara Rao,et al.  Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study. , 2008, Journal of pharmaceutical and biomedical analysis.

[90]  P. Cmoch,et al.  Physicochemical characterization of ezetimibe and its impurities , 2011 .

[91]  Huibin Zhang,et al.  Qualitative and quantitative studies on impurities in G004, a potential hypoglycaemic agent, using liquid chromatography, nuclear magnetic resonance and mass spectrometry. , 2011, Journal of pharmaceutical and biomedical analysis.

[92]  A. Mohan,et al.  Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product. , 2008, Journal of pharmaceutical and biomedical analysis.

[93]  Nafisur Rahman,et al.  The importance of impurity analysis in pharmaceutical products: an integrated approach , 2006 .

[94]  C. George,et al.  Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 3. Aromatic amine analogues. , 1990, Journal of medicinal chemistry.

[95]  E. Jaroszkiewicz,et al.  Radiochemical stability of fluconazole in the solid state. , 2007, Journal of pharmaceutical and biomedical analysis.

[96]  C. Szántay,et al.  Spectroscopic Methods in Drug Quality Control and Development , 2010 .

[97]  I. Wilson,et al.  Directly coupled CZE-NMR and CEC-NMR spectroscopy for metabolite analysis: paracetamol metabolites in human urine. , 1998, The Analyst.

[99]  J. M. Babu,et al.  Structural identification and characterization of potential impurities of pantoprazole sodium. , 2007, Journal of pharmaceutical and biomedical analysis.

[100]  Thomas J. Wenzel,et al.  Discrimination of Chiral Compounds Using NMR Spectroscopy , 2007 .

[101]  M. Malet‐Martino,et al.  Quality assessment of fluoxetine and fluvoxamine pharmaceutical formulations purchased in different countries or via the Internet by 19F and 2D DOSY 1H NMR. , 2008, Journal of pharmaceutical and biomedical analysis.

[102]  N. Srinivas,et al.  Identification and characterization of new impurity in didanosine. , 2007, Journal of pharmaceutical and biomedical analysis.

[103]  M. W. Dong,et al.  Handbook Of Pharmaceutical Analysis By Hplc , 2008 .

[104]  Magali Sautel,et al.  Pharmaceutical analysis beyond compendial requirements. , 2005, Journal of separation science.

[105]  M. Dreux,et al.  A comparative study of commercial liquid chromatographic detectors for the analysis of underivatized amino acids. , 2002, Journal of chromatography. A.

[106]  M. Wann 20 Application of LC-NMR in pharmaceutical analysis , 2005 .

[107]  L. Tseng,et al.  On-line coupling of capillary electrochromatography, capillary electrophoresis, and capillary HPLC with nuclear magnetic resonance spectroscopy. , 1998, Analytical chemistry.

[108]  S. Provera,et al.  Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonist. , 2010, Journal of pharmaceutical and biomedical analysis.

[109]  T. Claridge High-Resolution NMR Techniques in Organic Chemistry , 1999 .

[110]  J. Brus,et al.  New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations. , 2011, International journal of pharmaceutics.

[111]  R. Rupakula,et al.  Determination and characterization of degradation products of anastrozole by LC-MS/MS and NMR spectroscopy. , 2011, Journal of pharmaceutical and biomedical analysis.

[112]  M. P. Maskarinec,et al.  Micellar electrokinetic capillary chromatography , 1986 .

[113]  William J. Welsh,et al.  Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their 1H NMR spectra , 2011, Analytical and bioanalytical chemistry.

[114]  S. Görög,et al.  Estimation of impurity profiles in drugs and related materials. , 1998, Journal of pharmaceutical and biomedical analysis.

[115]  Mario Cindrić,et al.  Identification of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry. , 2005, Journal of pharmaceutical and biomedical analysis.

[116]  S. Provera,et al.  A multi-technique approach using LC-NMR, LC-MS, semi-preparative HPLC, HR-NMR and HR-MS for the isolation and characterization of low-level unknown impurities in GW876008, a novel corticotropin-release factor 1 antagonist. , 2010, Journal of pharmaceutical and biomedical analysis.

[117]  Santosh Kumar Bharti,et al.  Quantitative 1H NMR spectroscopy , 2012 .

[118]  U. Holzgrabe,et al.  Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[119]  R. Mumper,et al.  Poly(L-lactic Acid) Microspheres Containing Neutron-Activatable Holmium-165: A Study of the Physical Characteristics of Microspheres Before and After Irradiation in a Nuclear Reactor , 2004, Pharmaceutical Research.

[120]  K. Peremans,et al.  Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. , 2008, Analytical biochemistry.

[121]  Dong-hua Wang,et al.  Isolation, synthesis and structure confirmation of the impurity in crude roflumilast product , 2013, Research on Chemical Intermediates.

[122]  J. Battiste,et al.  2D 19F/19F NOESY for the assignment of NMR spectra of fluorochemicals , 2004 .

[123]  U. Holzgrabe,et al.  NMR techniques in biomedical and pharmaceutical analysis. , 2011, Journal of pharmaceutical and biomedical analysis.

[124]  Micellar electrokinetic capillary chromatography, high performance liquid chromatography and nuclear magnetic resonance--three orthogonal methods for characterization of critical drugs. , 2004, Journal of pharmaceutical and biomedical analysis.

[125]  Haiying Liu,et al.  Lessons learned from the contamination of heparin. , 2009, Natural product reports.

[126]  L. Tseng,et al.  Direct coupling of capillary electrophoresis and nuclear magnetic resonance spectroscopy for the identification of a dinucleotide , 1999 .

[127]  Karen M. Alsante,et al.  Handbook of Isolation and Characterization of Impurities in Pharmaceuticals , 2003 .

[128]  A. Srivastava,et al.  Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium. , 2008, Journal of pharmaceutical and biomedical analysis.

[129]  K. Albert,et al.  Online coupling of gas chromatography to nuclear magnetic resonance spectroscopy: method for the analysis of volatile stereoisomers. , 2008, Analytical chemistry.

[130]  A. Rück,et al.  Using high-performance quantitative NMR (HP-qNMR®) for certifying traceable and highly accurate purity values of organic reference materials with uncertainties <0.1 % , 2013, Accreditation and Quality Assurance.

[131]  Ashok Kumar,et al.  Application of GC-EI-MS for the identification and investigation of positional isomer in primaquine, an antimalarial drug. , 2005, Journal of pharmaceutical and biomedical analysis.

[132]  Ravi P. Shah,et al.  Identification and characterization of a photolytic degradation product of telmisartan using LC-MS/TOF, LC-MSn, LC-NMR and on-line H/D exchange mass studies. , 2010, Journal of pharmaceutical and biomedical analysis.

[133]  R. N. Rao,et al.  Chapter 19 – Monitoring of Process Impurities in Drugs , 1998 .

[134]  D. Satheesh,et al.  Identification, isolation and characterization of process related impurities in ezetimibe. , 2014, Journal of pharmaceutical and biomedical analysis.

[135]  Jacek Namieśnik,et al.  LC-MS and LC-NMR as Complementary Techniques for the Determination of Pharmaceuticals in Dosage Formulations , 2013 .

[136]  U. Holzgrabe,et al.  Quantitative NMR spectroscopy--applications in drug analysis. , 2005, Journal of pharmaceutical and biomedical analysis.

[137]  K. Albert On-line LC-NMR and related techniques , 2002 .

[138]  Caitlin M Sullivan,et al.  Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. , 2006, Journal of pharmaceutical and biomedical analysis.

[139]  Ashok Kumar,et al.  Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR. , 2010, Journal of pharmaceutical and biomedical analysis.

[140]  M. Malet‐Martino,et al.  Generic ciprofloxacin tablets contain the stated amount of drug and different impurity profiles: A 19F, 1H and DOSY NMR analysis. , 2007, Journal of pharmaceutical and biomedical analysis.

[141]  D. Colombo,et al.  Evaluation, synthesis and characterization of tacrolimus impurities , 2012, The Journal of Antibiotics.

[142]  J. Guan,et al.  A multidisciplinary approach to identify a degradation product in a pharmaceutical dosage form. , 2011, Journal of Pharmaceutical and Biomedical Analysis.

[143]  D. Armstrong,et al.  Enantiomeric impurities in chiral synthons, catalysts, and auxiliaries. Part 3. , 2006, Tetrahedron, asymmetry.

[144]  Guido F Pauli,et al.  Quantitative 1H NMR. Development and potential of an analytical method: an update. , 2012, Journal of natural products.

[145]  J. Klimeš,et al.  HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. , 2008, Journal of pharmaceutical and biomedical analysis.

[146]  R. N. Rao,et al.  Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy. , 2009, Journal of pharmaceutical and biomedical analysis.

[147]  F. Kusu,et al.  Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. , 2008, Journal of chromatography. A.

[148]  J. Saurina,et al.  Potentiality of proton nuclear magnetic resonance and multivariate calibration methods for the determination of dermatan sulfate contamination in heparin samples. , 2000, The Analyst.

[149]  F. Malz,et al.  Structure analytical methods for quantitative reference applications , 2005 .

[150]  R. C. Moreton United States Pharmacopeia-National Formulary , 2016 .

[151]  S. Ahuja Assuring quality of drugs by monitoring impurities. , 2007, Advanced drug delivery reviews.

[152]  P. Novak,et al.  The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid. , 2006, Journal of pharmaceutical and biomedical analysis.

[153]  H. Naoki,et al.  Photo-degradation products of pramipexole. , 2012, Bioorganic & medicinal chemistry letters.

[154]  K. Holme,et al.  Monitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. , 1989, Journal of pharmaceutical sciences.

[155]  U. Holzgrabe,et al.  Alternatives to amino acid analysis for the purity control of pharmaceutical grade L-alanine. , 2010, Journal of separation science.

[156]  A. Wand,et al.  Optimal Use of Cryogenic Probe Technology in NMR Studies of Proteins , 2000 .

[157]  U. Holzgrabe,et al.  Determination of free fatty acids in pharmaceutical lipids by ¹H NMR and comparison with the classical acid value. , 2014, Journal of pharmaceutical and biomedical analysis.

[158]  Richard L. Magin,et al.  Nanoliter Volume Sample cells for 1H NMR: Application to Online Detection in Capillary Electrophoresis , 1994 .

[159]  S. Bari,et al.  Impurity profile: Significance in Active Pharmaceutical Ingredient , 2007 .

[160]  J. V. Rompay Purity determination and evaluation of new drug substances. , 1986 .

[161]  T. Arvidsson,et al.  Use and qualification of primary and secondary standards employed in quantitative ¹H NMR spectroscopy of pharmaceuticals. , 2014, Journal of pharmaceutical and biomedical analysis.

[162]  A. Mazzanti,et al.  Identification of an isomer impurity in piperaquine drug substance. , 2006, Journal of chromatography. A.

[163]  C. Larive,et al.  Analysis and characterization of heparin impurities , 2010, Analytical and bioanalytical chemistry.

[164]  R. Pazdur,et al.  Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma , 2004, Clinical Cancer Research.

[165]  F. Corana,et al.  LC-MS characterization of trace impurities contained in calcium folinate. , 2005, Journal of pharmaceutical and biomedical analysis.

[166]  J. Galambos,et al.  NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II. , 2013, Journal of pharmaceutical and biomedical analysis.

[167]  J. Saurina,et al.  Proton nuclear magnetic resonance characterisation of glycosaminoglycans using chemometric techniques. , 2002, The Analyst.

[168]  J. M. Babu,et al.  Identification and characterization of potential impurities of rabeprazole sodium. , 2007, Journal of pharmaceutical and biomedical analysis.

[169]  D. Vir,et al.  Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI–IT/MS, 1H, 13C and 1H–1H COSY NMR , 2013, Journal of pharmaceutical analysis.

[170]  E. Yashima,et al.  NMR Studies of Chiral Discrimination Relevant to the Liquid Chromatographic Enantioseparation by a Cellulose Phenylcarbamate Derivative , 1996 .

[171]  A. Krstulović,et al.  Defining drug purity through chromatographic and related methods: current status and perspectives. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[172]  J. Keeler Understanding NMR Spectroscopy , 2005 .

[173]  Karen M. Alsante,et al.  Tools and workflow for structure elucidation of drug degradation products , 2013 .

[174]  K. Albert,et al.  Online coupling of enantioselective capillary gas chromatography with proton nuclear magnetic resonance spectroscopy. , 2010, Chirality.

[175]  Yuanchao Li,et al.  Characterization of related impurities in megestrol acetate. , 2006, Journal of pharmaceutical and biomedical analysis.

[176]  Ashok Kumar,et al.  Isolation and structural identification of an impurity in fluconazole bulk drug substance. , 2007, Journal of pharmaceutical and biomedical analysis.

[177]  G. Balogh,et al.  Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate. , 2002, Journal of pharmaceutical and biomedical analysis.

[178]  What is the degradation product of ezetimibe? , 2011, Journal of pharmaceutical and biomedical analysis.

[179]  H. van de Velde,et al.  Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile , 2011, AAPS PharmSciTech.

[180]  P. K. Basniwal,et al.  Forced degradation and impurity profiling: recent trends in analytical perspectives. , 2013, Journal of pharmaceutical and biomedical analysis.

[181]  S. Görög Identification and determination of impurities in drugs , 2000 .

[182]  P. Schmieder,et al.  Conformational Analysis of the cis‐ and trans‐Isomers of FK506 by NMR and Molecular Dynamics , 1991 .

[183]  E. Brenna,et al.  Isolation and characterisation of a phenolic impurity in a commercial sample of duloxetine. , 2007, Journal of pharmaceutical and biomedical analysis.

[184]  D. Armstrong,et al.  Enantiomeric impurities in chiral catalysts, auxiliaries, synthons and resolving agents. Part 2 , 1999 .

[185]  B. Segmuller,et al.  Identification of autoxidation and photodegradation products of ethynylestradiol by on-line HPLC-NMR and HPLC-S. , 2000, Journal of pharmaceutical and biomedical analysis.

[186]  S. Berger,et al.  50 and More Essential NMR Experiments: A Detailed Guide , 2013 .

[187]  H. Sharma,et al.  Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate. , 2009, Journal of Pharmaceutical and Biomedical Analysis.

[188]  U. Holzgrabe,et al.  1H-NMR Spectroscopy as a New Tool in the Assessment of the Oxidative State in Edible Oils , 2012 .

[189]  A. Berthod Chiral Recognition in Separation Methods , 2010 .

[190]  S. Ahuja Impurities evaluation of pharmaceuticals , 1998 .

[191]  T. Kaufman,et al.  Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs. , 2009, Analytica chimica acta.

[192]  C. B'hymer,et al.  Residual Solvent Testing: A Review of Gas-Chromatographic and Alternative Techniques , 2003, Pharmaceutical Research.

[193]  I. Singh,et al.  Determining and reporting purity of organic molecules: why qNMR , 2013, Magnetic resonance in chemistry : MRC.

[194]  Zuzana Mandelová,et al.  Identification, preparation and UHPLC determination of process-related impurity in zolmitriptan. , 2012, Journal of pharmaceutical and biomedical analysis.

[195]  D. Armstrong,et al.  Enantiomeric impurities in chiral catalysts, auxiliaries, and synthons used in enantioselective syntheses. Part 4 , 1998 .

[196]  G. Bertho,et al.  A new derivative detected in accelerated ageing of artesunate-amodiaquine fixed dose combination tablets. , 2013, Journal of pharmaceutical and biomedical analysis.

[197]  J. McAlpine,et al.  Design of countercurrent separation of Ginkgo biloba terpene lactones by nuclear magnetic resonance. , 2012, Journal of chromatography. A.

[198]  M. Yoshikawa,et al.  Development and testing of superfluid-cooled 900 MHz NMR magnet , 2001 .

[199]  B. Pramanik,et al.  Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS. , 2001, Journal of pharmaceutical and biomedical analysis.

[200]  R. Mukherjee,et al.  Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. , 2007, Journal of pharmaceutical and biomedical analysis.

[201]  J. Battiste,et al.  Applications of 19F multidimensional NMR , 2006 .

[202]  Sarfaraz Niazi,et al.  Impurities in New Drug Products , 2016 .

[203]  T. Schoenberger Determination of standard sample purity using the high-precision 1H-NMR process , 2012, Analytical and Bioanalytical Chemistry.

[204]  S. Parapini,et al.  The Fe2+‐Mediated Decomposition, PfATP6 Binding, and Antimalarial Activities of Artemisone and Other Artemisinins: The Unlikelihood of C‐Centered Radicals as Bioactive Intermediates , 2007, ChemMedChem.

[205]  G. Tárkányi,et al.  Quantitative approach for the screening of cyclodextrins by nuclear magnetic resonance spectroscopy in support of chiral separations in liquid chromatography and capillary electrophoresis enantioseparation of norgestrel with alpha-, beta- and gamma-cyclodextrins. , 2002, Journal of chromatography. A.

[206]  Jingqi Huang,et al.  Identification of adulterants in a Chinese herbal medicine by LC-HRMS and LC-MS-SPE/NMR and comparative in vivo study with standards in a hypertensive rat model. , 2010, Journal of pharmaceutical and biomedical analysis.

[207]  A. Vannacci,et al.  Combined HPLC-DAD-MS, HPLC-MS(n) and NMR spectroscopy for quality control of plant extracts: the case of a commercial blend sold as dietary supplement. , 2014, Journal of pharmaceutical and biomedical analysis.

[208]  T. Kaufman,et al.  Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition. , 2011, Journal of pharmaceutical and biomedical analysis.

[209]  G. Pauli,et al.  Purification of berry flavonol glycosides by long-bed gel permeation chromatography. , 2012, Journal of chromatography. A.

[210]  Richard J. Smith,et al.  Use of liquid chromatography-nuclear magnetic resonance spectroscopy for the identification of impurities in drug substances , 1994 .

[211]  H. Avdovich,et al.  Nuclear magnetic resonance identification and estimation of solvent residues in cocaine , 1991 .

[212]  T. Wenzel,et al.  Using NMR spectroscopic methods to determine enantiomeric purity and assign absolute stereochemistry. , 2011, Progress in nuclear magnetic resonance spectroscopy.

[213]  A. Mohan,et al.  Identification, Isolation, and Characterization of Five Potential Degradation Impurities in Candesartan Cilexetil Tablets , 2009 .

[214]  D. Greenwood,et al.  Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR. , 2012, Journal of pharmaceutical and biomedical analysis.

[215]  Jimmy D. Bell,et al.  Modern Magnetic Resonance , 2006 .

[216]  Karen M. Alsante,et al.  Degradation and Impurity Analysis for Pharmaceutical Drug Candidates , 2011 .

[217]  Isolation, structure characterization and quantification of related impurities in asperosaponin VI. , 2013, Chinese journal of natural medicines.

[218]  S. Baertschi Analytical methodologies for discovering and profiling degradation-related impurities , 2006 .

[219]  D. Keire,et al.  Characterization of currently marketed heparin products: key tests for LMWH quality assurance. , 2013, Journal of pharmaceutical and biomedical analysis.

[220]  E. Brenna,et al.  Isolation and characterisation of impurities in adapalene. , 2007, Journal of pharmaceutical and biomedical analysis.

[221]  R Nageswara Rao,et al.  An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. , 2003, Journal of pharmaceutical and biomedical analysis.

[222]  Ravi P. Shah,et al.  A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. , 2012, Journal of pharmaceutical and biomedical analysis.

[223]  Ravi P. Shah,et al.  Identification and characterization of geometrical isomeric photo degradation product of eprosartan using LC-MS and LC-NMR , 2011 .

[224]  Michal Douša,et al.  Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold. , 2011, Journal of pharmaceutical and biomedical analysis.

[225]  Lucinda F Buhse,et al.  Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. , 2011, Journal of pharmaceutical and biomedical analysis.

[226]  S. Zeng,et al.  Identification and characterization of four process-related impurities in retigabine. , 2012, Journal of pharmaceutical and biomedical analysis.

[227]  Fengqing Yang,et al.  Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. , 2011, The Analyst.

[228]  M. Bernstein,et al.  Enantiomeric purity determination by NMR: proving the purity of a single enantiomer , 2013 .

[229]  Cuirong Sun,et al.  Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry. , 2005, Journal of pharmaceutical and biomedical analysis.